| pubmed-article:7751994 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7751994 | lifeskim:mentions | umls-concept:C0062527 | lld:lifeskim |
| pubmed-article:7751994 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:7751994 | lifeskim:mentions | umls-concept:C0026591 | lld:lifeskim |
| pubmed-article:7751994 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:7751994 | lifeskim:mentions | umls-concept:C0021270 | lld:lifeskim |
| pubmed-article:7751994 | lifeskim:mentions | umls-concept:C0019167 | lld:lifeskim |
| pubmed-article:7751994 | lifeskim:mentions | umls-concept:C0205296 | lld:lifeskim |
| pubmed-article:7751994 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:7751994 | pubmed:issue | 5 Pt 1 | lld:pubmed |
| pubmed-article:7751994 | pubmed:dateCreated | 1995-6-19 | lld:pubmed |
| pubmed-article:7751994 | pubmed:abstractText | To evaluate the long-term protection afforded by the vaccine, recombinant hepatitis B (HB) vaccine was given to 171 infants born to hepatitis B e antigen-positive carrier mothers. Group A (53 infants) and group B (57 infants) received four doses of HB vaccine at birth and at 1, 2, and 12 months of age, with a dose of 20 micrograms in group A and 10 micrograms in group B. Group C (61 infants) received three 20 micrograms doses of HB vaccine at birth and at 1 and 6 months of age. These children were followed up annually up to 5 years of age. Six children (4%) became HB carriers before 1 year of age, and the carrier state persisted to the end of follow-up. The overall seropositive rate of HB surface antibody (anti-HBs) dropped from 99% at 1 year of age to 83% at 5 years of age. Among 548 serum pairs taken at 1-year intervals from children negative for HB surface antigen (HBsAg), a fourfold rise of anti-HBs titer was noted in 58 (11%) and a 10-fold rise of anti-HBs was noted in 17 (3%). Maternal HB core antibody disappeared in most children (151/152, 99%) before 2 years of age. Natural infections, as judged by persistence or reappearance of HB core antibody, occurred in 19 of 163 (12%) HBsAg-negative children. None of these episodes was associated with HBsAg positivity. We conclude that the long-term protection afforded by recombinant HB vaccine is satisfactory and that a further booster dose before 5 years of age is not necessary. | lld:pubmed |
| pubmed-article:7751994 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7751994 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7751994 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7751994 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7751994 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7751994 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7751994 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7751994 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7751994 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7751994 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7751994 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7751994 | pubmed:month | May | lld:pubmed |
| pubmed-article:7751994 | pubmed:issn | 0022-3476 | lld:pubmed |
| pubmed-article:7751994 | pubmed:author | pubmed-author:LeeC YCY | lld:pubmed |
| pubmed-article:7751994 | pubmed:author | pubmed-author:ChangM HMH | lld:pubmed |
| pubmed-article:7751994 | pubmed:author | pubmed-author:GeeG KGK | lld:pubmed |
| pubmed-article:7751994 | pubmed:author | pubmed-author:HuangL MLM | lld:pubmed |
| pubmed-article:7751994 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7751994 | pubmed:volume | 126 | lld:pubmed |
| pubmed-article:7751994 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7751994 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7751994 | pubmed:pagination | 716-21 | lld:pubmed |
| pubmed-article:7751994 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:meshHeading | pubmed-meshheading:7751994-... | lld:pubmed |
| pubmed-article:7751994 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7751994 | pubmed:articleTitle | Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. | lld:pubmed |
| pubmed-article:7751994 | pubmed:affiliation | Department of Pediatrics, National Taiwan University Hospital, Taipei, Republic of China. | lld:pubmed |
| pubmed-article:7751994 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7751994 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7751994 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:7751994 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7751994 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7751994 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7751994 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7751994 | lld:pubmed |
